4,712 reports of this reaction
3.4% of all CISPLATIN reports
#3 most reported adverse reaction
NEUTROPENIA is the #3 most commonly reported adverse reaction for CISPLATIN, manufactured by Accord Healthcare Inc.. There are 4,712 FDA adverse event reports linking CISPLATIN to NEUTROPENIA. This represents approximately 3.4% of all 137,577 adverse event reports for this drug.
Patients taking CISPLATIN who experience neutropenia should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
NEUTROPENIA is moderately reported among CISPLATIN users, representing a notable but not dominant share of adverse events.
In addition to neutropenia, the following adverse reactions have been reported for CISPLATIN:
The following drugs have also been linked to neutropenia in FDA adverse event reports:
NEUTROPENIA has been reported as an adverse event in 4,712 FDA reports for CISPLATIN. This does not prove causation, but indicates an association observed in post-market surveillance data.
NEUTROPENIA accounts for approximately 3.4% of all adverse event reports for CISPLATIN, making it one of the most commonly reported side effect.
If you experience neutropenia while taking CISPLATIN, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.